Ghehi Calixte, Gabillard Delphine, Moh Raoul, Badje Anani, Kouamé Gérard Menan, Oouttara Eric, Ahibo Hugues, N'Takpé Jean Baptiste, Lecarrou Jérôme, Eholié Serge Paul, Anglaret Xavier, Danel Christine
Programme PACCI - ANRS research site, Abidjan, Côte d'Ivoire.
Inserm U1219, Université de Bordeaux, Bordeaux, France.
PLoS One. 2017 Jun 5;12(6):e0177440. doi: 10.1371/journal.pone.0177440. eCollection 2017.
Data on cardiovascular risk (CVR) score among HIV-infected patients in sub-Saharan Africa are scarce. Our first objective was to compare the CVR score of Framingham utilizing BMI and lipids at baseline, and secondary to assess evolution of CVR score over time at Month 30 in the Temprano trial.
HIV-infected adults with CD4 <800/mm3 without criteria for initiating ART were included and followed for 30 months in the Temprano trial, which assessed the benefits and risks of early antiretroviral treatment (ART) vs deferred ART. CVR score was estimated at baseline and Month-30 using Framingham equations with either BMI or lipids and classified as high (>20%), moderate (10-20%), and low risk (<10%). At baseline, we compare these two estimations utilizing the Pearson correlation test and analyze the increasing CV risk score over time by Proportional odds cumulative logit models for people attending the Month-30 (M30) visit.
Among the 2056 patients, 78% were women, median age was 35 years, and median CD4 count was 464/mm3, 6.8% were obese, 6.3% had hypertension, 7.8% were smokers (1.8% women, 26.8% men), 19% had Total Cholesterol (TC) >5mmol/L, and 1% diabetes at baseline. At baseline the concordance between the two Framingham equations was excellent (r = 0.95; p<0.0001). Among the 1700 patients who attended M30 visit and with available data, 1.3% had a high CV risk score at baseline and 3.1% at M30 visit using Framingham equation with BMI. Adjusted odds ratio (aOR) of being at a higher CV risk score at M30 visit compared to a higher CV risk score at M0 visit was 1.35 (CI 95% 1.17-1.57). Stratified by sex, the increasing CV risk score was OR 1.73 (CI 95%: 1.30-2.29) for women and OR 1.24 (CI 95%: 1.02-1.50) for men. Early ART was not associated with an increasing CV risk score (p = 0.88). Results for the 1422 patients with Framingham equation using lipids were similar.
In a large trial evaluating early ART for HIV infection in Côte d'Ivoire, Framingham equation with BMI and lipids were highly correlated and CV risk score increases over time. Early ART was not significantly associated with this increasing CV risk score.
撒哈拉以南非洲地区感染艾滋病毒患者的心血管风险(CVR)评分数据稀缺。我们的首要目标是比较弗雷明汉姆心血管风险评分在基线时利用体重指数(BMI)和血脂的情况,其次是在Temprano试验中评估30个月时CVR评分随时间的变化。
在Temprano试验中纳入了CD4<800/mm³且无启动抗逆转录病毒治疗(ART)标准的成年艾滋病毒感染者,并随访30个月,该试验评估了早期抗逆转录病毒治疗(ART)与延迟抗逆转录病毒治疗的益处和风险。使用包含BMI或血脂的弗雷明汉姆方程在基线和第30个月时估计CVR评分,并分为高风险(>20%)、中度风险(10-20%)和低风险(<10%)。在基线时,我们使用Pearson相关检验比较这两种估计方法,并通过比例优势累积logit模型分析在第30个月(M30)就诊的人群中随时间增加的心血管风险评分。
在2056名患者中,78%为女性,中位年龄为35岁,中位CD4细胞计数为464/mm³,6.8%为肥胖者,6.3%患有高血压,7.8%为吸烟者(1.8%为女性,26.8%为男性),19%的总胆固醇(TC)>5mmol/L,基线时1%患有糖尿病。在基线时,两个弗雷明汉姆方程之间的一致性非常好(r = 0.95;p<0.0001)。在1700名参加M30就诊且有可用数据的患者中,使用包含BMI的弗雷明汉姆方程时,1.3%在基线时具有高心血管风险评分,在M30就诊时为3.1%。与M0就诊时较高的心血管风险评分相比,M30就诊时处于较高心血管风险评分的调整优势比(aOR)为1.35(95%置信区间1.17-1.57)。按性别分层,女性心血管风险评分增加的优势比为1.73(95%置信区间:1.30-2.29),男性为1.24(95%置信区间:1.02-1.50)。早期抗逆转录病毒治疗与心血管风险评分增加无关(p = 0.88)。使用血脂的1422名患者的弗雷明汉姆方程结果相似。
在一项评估科特迪瓦艾滋病毒感染早期抗逆转录病毒治疗的大型试验中,包含BMI和血脂的弗雷明汉姆方程高度相关,且心血管风险评分随时间增加。早期抗逆转录病毒治疗与这种心血管风险评分增加无显著关联。